Insider · CIK 0001760123
Dietrich John Pauls
Files at DMAC (DiaMedica Therapeutics Inc.). First filing -, latest -.
In brief
Dietrich John Pauls files SEC Form 4 as CEO, president and director at DMAC (DiaMedica Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Dietrich John Pauls has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Voting Common Shares, no par value per share | +60,200 | $0.00 | $0 | 128,791 | Aug 12, 2026 |
| Jun 1, 2026 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +380,000 | $0.00 | $0 | 380,000 | Jun 3, 2026 |
| Jun 1, 2025 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Jun 3, 2025 |
Questions about Dietrich John Pauls
Answered from the filings on this page, as of the latest one.
Is Dietrich John Pauls buying or selling?
Dietrich John Pauls has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Dietrich John Pauls's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dietrich John Pauls has 0.
Where does Dietrich John Pauls file Form 4?
Dietrich John Pauls has filed Form 4 at DMAC (DiaMedica Therapeutics Inc.) as President & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.